:: UTM Library Massive Scholar Tracking

Abstract non disponibile

Bibliographic Details
Main Authors:	Angelis Konstantinopoulos, Konstantinos Giannitsas, Spiros Raptis, Petros Perimenis
Format:	Article
Language:	English
Published:	AboutScience Srl 2007-01-01
Series:	Drug Target Insights
Subjects:	Endothelial dysfunction erectile dysfunction phosphodiesterase 5 inhibitors
Online Access:	https://journals.aboutscience.eu/index.php/dti/article/view/1310

Similar Items

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
by: Angelis Konstantinopoulos, et al.
Published: (2007-01-01)

Influence of regular use of vardenafil on endothelial and erectile functions in patients with arteriogenic erectile dysfunction
by: Safar Israilovich Gamidov, et al.
Published: (2009-10-01)

PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE
by: M. N. Mamedov, et al.
Published: (2016-01-01)

An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy
by: Wen-Jun Bai, et al.
Published: (2015-02-01)

Obesity and Erectile Dysfunction: From Bench to Clinical Implication
by: Ki Hak Moon, et al.
Published: (2019-05-01)

The blue pill (sildenafil) and its descendants: an overview
by: Krzanowski Tomasz, et al.
Published: (2017-09-01)

EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil
by: Giovanni Corona, MD, PhD, et al.
Published: (2018-03-01)

Variations in Low Intensity Shockwave Treatment Protocols for Erectile Dysfunction: A Review of the Literature and Guide to Offering Treatment
by: Solomon Hayon, et al.
Published: (2024-04-01)

Does the Daily Dose of Tadalafil for the Treatment of Erectile Dysfunction Increase Penile Sensation?
by: Selim Taş, et al.
Published: (2023-03-01)

Molecular and Histologic Evidence of Novel Erectile Dysfunction Rat Model as an Aging Atherosclerosis Model: A Preliminary Study
by: Jae Heon Kim, et al.
Published: (2020-07-01)

Penile Erection Induced by Scoparone from Artemisia capillaris through the Nitric Oxide-Cyclic Guanosine Monophosphate Signaling Pathway
by: Bo Ram Choi, et al.
Published: (2017-12-01)

Erectile dysfunction in diabetes mellitus: A review
by: Deepak K Jumani, et al.
Published: (2020-01-01)

Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors
by: Luigi Maresca, et al.
Published: (2013-12-01)

Recreational use of oral erectile dysfunction medications among male physicians - A cross-sectional study
by: Raed Almannie, et al.
Published: (2023-01-01)

Pathological Significance of Macrophages in Erectile Dysfunction Including Peyronie’s Disease
by: Yasuyoshi Miyata, et al.
Published: (2021-11-01)

REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome
by: Ridwan Shabsigh, MD, FACS, et al.
Published: (2016-09-01)

Phosphodiesterase-5 Inhibitor Use in Robot Assisted Radical Prostatectomy Patients Is Associated with Reduced Risk of Death: A Propensity Score Matched Analysis of 1,058 Patients
by: Jongsoo Lee, et al.
Published: (2023-10-01)

Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction
by: Connie C. J. Louizos, et al.
Published: (2015-11-01)

The pharmacological management of erectile dysfunction
by: Andre Marais
Published: (2015-07-01)

Pharmacotherapy of erectile dysfunction: Current standards
by: Kew-Kim Chew
Published: (2006-01-01)

Peyronie′s disease and erectile dysfunction: Current understanding and future direction
by: Laurence A Levine
Published: (2006-01-01)

Postprostatectomy Erectile Dysfunction: A Review
by: Paolo Capogrosso, et al.
Published: (2016-08-01)

Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie′s disease
by: Lucio Dell′Atti
Published: (2015-01-01)

Investigation of Cnidium monnieri compounds as phosphodiesterase-5 antagonists in erectile dysfunction via molecular docking and dynamic simulation
by: Damilola Alex Omoboyowa
Published: (2024-01-01)

Inflammatory biomarkers may predict response to phosphodiesterase type 5 inhibitor treatment in patients with erectile dysfunction
by: Metin Kilic, et al.
Published: (2023-07-01)

A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
by: Jin-Qiu Yuan, et al.
Published: (2016-01-01)

Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
by: Yatan Pal Singh Balhara, et al.
Published: (2015-01-01)

Effects of different treatments on endothelial function in patients with erectile dysfunction and hypogonadism
by: E B Mazo, et al.
Published: (2008-12-01)

Erectile function in men with COVID-19 six months after recovery
by: E.V. Luchytskyi, et al.
Published: (2023-12-01)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
by: Moschos MM, et al.
Published: (2016-10-01)

Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts
by: Kurt Miller, et al.
Published: (2023-10-01)

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
by: Ahmed K. ElHady, et al.
Published: (2023-09-01)

An Empirical vs Risk-Based Approach Algorithm to Intracavernosal Injection Therapy: A Prospective Study
by: Helen Levey Bernie, DO, MPH, et al.
Published: (2017-03-01)

Audiovisual Sexual Stimulation and RigiScan Test for the Diagnosis of Erectile Dysfunction
by: Tao Wang, et al.
Published: (2018-01-01)

Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism
by: Chunlin Wang, et al.
Published: (2024-12-01)

Does Testosterone Salvage PDE5i Non-Responders? A Scoping Review
by: Mike Pignanelli, et al.
Published: (2023-02-01)

Hyperhomocysteinemia: Focus on Endothelial Damage as a Cause of Erectile Dysfunction
by: Gianmaria Salvio, et al.
Published: (2021-01-01)

Erectile dysfunction as a manifestation of urogenital autonomic neuropathy in patients with type 1 diabetes: epidemiology, classification, pathophysiology, diagnosis and treatment options
by: Gagik Radikovich Galstyan, et al.
Published: (2014-07-01)

Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats
by: Tomoya Kataoka, PhD, et al.
Published: (2022-04-01)

Treatment of Erectile Dysfunction in Type 2 Diabetic Men
by: V.Ye. Luchytskyi
Published: (2015-11-01)